GlassScriptPhysician profile
John Bajgrowicz
NPI 1245288331
$8,570.39
in general payments reported to CMS, 2019-2025
34 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $805 · 2021: $1,237 · 2022: $725 · 2023: $1,535 · 2024: $1,363 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.55 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,353.54 | 2019-2024 | Xarelto, Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $1,064.74 | 2019-2025 | |
| Amgen INC. | $868.85 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.59 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $683.67 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $637.91 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $542.27 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $405.81 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $356.03 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Kowa Pharmaceuticals America, INC. | $284.48 | 2019-2021 | |
| Esperion Therapeutics, INC. | $264.94 | 2020-2025 | Nexletol |
| Lundbeck LLC | $220.24 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $194.35 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $116.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $97.61 | 2020-2023 | Uptravi, Opsumit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $95.50 | 2025 | Amvia Edge |
| Kiniksa Pharmaceuticals International, Plc | $87.89 | 2024 | Arcalyst |
| Astellas Pharma US INC | $80.01 | 2021-2022 | |
| Edwards Lifesciences Corporation | $65.19 | 2019-2020 | |
| Scpharmaceuticals INC. | $61.47 | 2025 | |
| Medtronic, INC. | $40.01 | 2021 | |
| Boston Scientific Corporation | $37.23 | 2023-2024 | Bodyguardian |
| Amarin Pharma, INC. | $35.77 | 2019 | |
| Medicomp INC | $35.44 | 2020-2023 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $34.86 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $33.10 | 2024 | Assure Wcd |
| Corcept Therapeutics | $29.61 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $27.01 | 2025 | Inspire |
| Medtronic Vascular, INC. | $25.90 | 2019 | |
| Novo Nordisk INC | $24.81 | 2024 | Wegovy |
| Infobionic, INC | $23.19 | 2020 | |
| Lantheus Medical Imaging, INC. | $21.18 | 2023 | Definity |
| Glaxosmithkline, LLC. | $18.68 | 2025 | Shingrix |
| Irhythm Technologies, INC. | $13.18 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bajgrowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.